Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas

APMIS

Volumn 120, Issue 8, 2012, Pages 635-639

  Je, Eun M ^a   An, Chang H ^a   Yoo, Nam J ^a   Lee, Sug H ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

JAK2; Mutation; Oncogene; PIK3CA; Sarcoma

Indexed keywords

B RAF KINASE; FORKHEAD BOX PROTEIN L2; FORKHEAD TRANSCRIPTION FACTOR; ISOCITRATE DEHYDROGENASE 1; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANGIOSARCOMA; ARTICLE; CHONDROSARCOMA; CONTROLLED STUDY; DERMATOFIBROMA; DNA SEQUENCE; EWING SARCOMA; EXON; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MISSENSE MUTATION; MUTATIONAL ANALYSIS; ONCOGENE; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; SYNOVIAL SARCOMA;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; MUTATION; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; POLYCOMB REPRESSIVE COMPLEX 2; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SARCOMA;

EID: 84863831448     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02878.x     Document Type: Article

References (20)

1. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003;9:1941-56.
2. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715-21.
3. Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999;59:1428-32.
4. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995;15:1522-35.
5. Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993;4:175-80.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
9. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009;360:2719-29.
10. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
11. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
12. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5.
13. Müller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31:27-32.
14. Choy E, Hornicek F, Macconaill L, Harmon D, Tariq Z, Garraway L, et al. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 2012. 118:2905-14.
15. Daniels M, Lurkin I, Pauli R, Erbstösser E, Hildebrandt U, Hellwig K, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 2011;312:43-54.
16. Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M, et al. Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology 2011;58:1167-72.
17. Fletcher CDM, Unni KK, Mertens F. Pathology and Genetics of Tumors of Soft Tissue and Bone. World Health Organization Classification of Tumors. Lyon: IARC Press, 2002.
18. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80.
19. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999;18:3754-60.
20. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: cause and consequences. Human Genet 1992;90:41-54.